Found: 17
Select item for more details and to access through your institution.
The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial.
- Published in:
- American Journal of Cardiovascular Drugs, 2019, v. 19, n. 1, p. 49, doi. 10.1007/s40256-018-0298-8
- By:
- Publication type:
- Article
Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy.
- Published in:
- Pharmacology Research & Perspectives, 2022, v. 10, n. 3, p. 1, doi. 10.1002/prp2.949
- By:
- Publication type:
- Article
Transcriptional control of apolipoprotein A-I gene expression in diabetes.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Transcriptional Control of Apolipoprotein A-1 Gene Expression in Diabetes.
- Published in:
- Diabetes, 2004, v. 53, n. 3, p. 513, doi. 10.2337/diabetes.53.3.513
- By:
- Publication type:
- Article
Phlorizin or vanadate treatment reverses impaired expression of albumin and hepatocyte nuclear factor 1 in diabetic rats.
- Published in:
- 1996
- By:
- Publication type:
- journal article
Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases.
- Published in:
- Medicinal Research Reviews, 2021, v. 41, n. 1, p. 223, doi. 10.1002/med.21730
- By:
- Publication type:
- Article
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial.
- Published in:
- Cardiovascular Diabetology, 2021, v. 20, n. 1, p. 1, doi. 10.1186/s12933-021-01311-9
- By:
- Publication type:
- Article
Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease.
- Published in:
- Cardiovascular Therapeutics, 2020, p. 1, doi. 10.1155/2020/9397109
- By:
- Publication type:
- Article
Insulin mimetic effect of D‐allulose on apolipoprotein A‐I gene.
- Published in:
- Journal of Food Biochemistry, 2022, v. 46, n. 2, p. 1, doi. 10.1111/jfbc.14064
- By:
- Publication type:
- Article
FO080 APABETALONE, AN INHIBITOR OF BET PROTEINS, IMPROVES CARDIOVASCULAR RISK AND REDUCES ALKALINE PHOSPHATASE IN BOTH CVD PATIENTS AND PRIMARY HUMAN CELL CULTURE SYSTEMS.
- Published in:
- Nephrology Dialysis Transplantation, 2019, v. 34, p. N.PAG, doi. 10.1093/ndt/gfz096.FO080
- By:
- Publication type:
- Article
Obesity-related Changes in High-density Lipoprotein Metabolism.
- Published in:
- Obesity (19307381), 2008, v. 16, n. 6, p. 1152, doi. 10.1038/oby.2008.202
- By:
- Publication type:
- Article
RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist.
- Published in:
- PLoS ONE, 2013, v. 8, n. 12, p. 1, doi. 10.1371/journal.pone.0083190
- By:
- Publication type:
- Article
Arterial Embolization: A Novel Approach to Thyroid Ablative Therapy for Graves’ Disease.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2002, v. 87, n. 8, p. 3583, doi. 10.1210/jcem.87.8.8723
- By:
- Publication type:
- Article
Insulin Production in a Neuroectodermal Tumor that Expresses Islet Factor-1, But Not Pancreatic-Duodenal Homeobox 1.
- Published in:
- 2001
- By:
- Publication type:
- journal article
BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes.
- Published in:
- Clinical Epigenetics, 2020, v. 12, n. 1, p. N.PAG, doi. 10.1186/s13148-020-00943-0
- By:
- Publication type:
- Article
Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.
- Published in:
- Clinical Epigenetics, 2019, v. 11, n. 1, p. N.PAG, doi. 10.1186/s13148-019-0696-z
- By:
- Publication type:
- Article
Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro.
- Published in:
- Biomedicines, 2021, v. 9, n. 4, p. 437, doi. 10.3390/biomedicines9040437
- By:
- Publication type:
- Article